[Cheongdam Corporate Building of Dongkook Pharmaceutical] ‘ESG Management’, 1 Trillion Won Sales by 2025
[Cheongdam Corporate Building of Dongkook Pharmaceutical] ‘ESG Management’, 1 Trillion Won Sales by 2025
  • Cho Eun, Reporter
  • 승인 2023.01.20 20:51
  • 수정 2023.01.20 20:51
  • 댓글 0
이 기사를 공유합니다

[Photo courtesy of Dongkook Pharmaceutical]
[Photo courtesy of Dongkook Pharmaceutical]

Dongkook Pharmaceutical, which has achieved annual sales of 660 billion won, accelerates ESG (Environmental, Social and Governance) management.

The company shall identify the ESG status by each of environment, society, and governance sectors, prepare the foundation for sustainable future management, and disclose information transparently and accurately.

Dongkook Pharmaceutical started an energy efficiency project with Veolia, a French environmental company, from 2021, and completed a waste biogas recycling system in July last year, replacing 10% of LNG consumption with biogas.

Based on the performance of carbon emission reduction and the wastewater treatment plant optimization project, it also expects to obtain ISO 14001 certification, which is an international standard.

The company established a dedicated safety and health management department directly under the CEO to strengthen the safety organization, and its compliance was recognized in the ‘ISO 37001’ renewal review, leading to recertification.

The company plans to disclose related information on its website or the Korea Institute of Corporate Governance and Sustainability.

In the midst of this development, Dongkook Pharmaceutical opened the era of Cheongdam-dong. A new corporate building was built on the site in Cheongdam-dong, Gangnam-gu, purchased for 40 billion won in 2018, and the company moved in this building in March last year.

The building has a total area of 9,314㎡ (land area of 1,161㎡) and 16 floors above ground with 4 floors below ground. Over 250 employees are currently working at the headquarters in this new building, and affiliates such as Dongkook Life Science are using the old corporate building (Daechi-dong, Gangnam-gu).

The relocation of the corporate building was possible thanks to Dongkook Pharmaceutical's continuous success in performance. The company achieved steep top-line growth with an average annual sales growth of 11.8%.

[Data provided by Shinhan Investment Corp.]
[Data provided by Shinhan Investment Corp.]

Cumulative sales on a consolidated basis for the third quarter of last year were 495.2 billion won and operating profit was 55.2 billion won. Compared to the previous year, these figures represent increase by 11.6% and 17.7%, respectively. The industry estimates that Dongkook’s sales will be 666 billion won and operating profit 80 billion won if the fourth quarter figures are added.

Dongkook Pharmaceutical aims to achieve 1 trillion won in sales by 2025 through the annual growth rate of 14.5%. It is continuing new investments such as new technology development and factory expansion.

The OTC division is strengthening its brand line-up in addition to its mega-brand products, and the ETC division is expanding its sales channels and market share by launching new products.

The growth in sales of the healthcare division, particularly the ‘Centellian 24’ brand, has also contributed. Diversification of the total healthcare business, including cosmetics, showed a growth of 11.5%, playing a crucial role in the highest performance in the first half of last year.

An official from Dongkuk Pharmaceutical said, "The four divisions, OTC, ETC, Healthcare, and Overseas, are growing evenly and generating stable profits. We plan to secure competitiveness in new product development and mass production through continuous investment in R&D facilities and increase domestic and overseas market shares.”

[WIKI KOREA=Cho Eun, Reporter]

choeun@wikileaks-kr.org


  • 서울특별시 마포구 마포대로 127, 1001호 (공덕동, 풍림빌딩)
  • 대표전화 : 02-702-2677
  • 팩스 : 02-702-1677
  • 청소년보호책임자 : 소정원
  • 법인명 : 위키리크스한국 주식회사
  • 제호 : 위키리크스한국
  • 등록번호 : 서울 아 04701
  • 등록일 : 2013-07-18
  • 발행일 : 2013-07-18
  • 발행인 : 박정규
  • 편집인 : 박찬흥
  • 위키리크스한국은 자체 기사윤리 심의 전문위원제를 운영합니다.
  • 기사윤리 심의 : 박지훈 변호사
  • 위키리크스한국 모든 콘텐츠(영상,기사, 사진)는 저작권법의 보호를 받은바, 무단 전재와 복사, 배포 등을 금합니다.
  • Copyright © 2024 위키리크스한국. All rights reserved.
  • [위키리크스한국 보도원칙] 본 매체는 독자와 취재원 등 뉴스 이용자의 권리 보장을 위해 반론이나 정정보도, 추후보도를 요청할 수 있는 창구를 열어두고 있음을 알립니다.
    고충처리 : 02-702-2677 | 메일 : laputa813@wikileaks-kr.org
ND소프트